SAN DIEGO, May 14, 2015 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced presentations at two upcoming healthcare events, the London Regenerative Medicine Network, and The World Stem Cells and Regenerative Medicine Congress 2015.
Dr. Paul Laikind, President and Chief Executive Officer, will speak at the London Regenerative Medicine Network. Dr. Laikind will review recent progress with the company’s VC-01™ product candidate for the treatment of type 1 diabetes, which entered the clinical phase of development late last year. The Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes, is ongoing.
During The World Stem Cells and Regenerative Medicine Congress 2015, Dr. Laikind will host a roundtable discussion on the topic “A virtual cure for Type 1 diabetes.”
Details of the events are as follows:
Event: London Regenerative Medicine Network
Date/Time: May 19, 2015 at 6:30 p.m.
Location: University College London, United Kingdom
Event: The World Stem Cells and Regenerative Medicine Congress 2015
Date/Time: May 21, 2015 at 11:30 a.m.
Location: Business Design Centre, London, United Kingdom
A number of advances have been made recently in the development of stem cell-based therapies for type 1 diabetes. ViaCyte’s VC-01™ product candidate, being assessed in the STEP ONE clinical trial, employs pluripotent stem cell-derived PEC-01™ pancreatic progenitor cells implanted within the Encaptra® macroencapsulation device. The VC-01 product has been demonstrated to regulate glucose levels in animal models. PEC-01 progenitor cells reflect a cell type present in a developing embryo and are thus believed to have an enhanced capability for surviving in a hypoxic environment such as the post-implant subcutaneous space, and for promoting the vascularization needed for the implanted cells to mature and thrive. In November 2014, ViaCyte announced that it had been granted U.S. patent 8,859,286, which claims additional methods for producing pancreatic cells, including cell types further differentiated beyond the progenitor stage to single-hormonal islet-like cells.
For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.